Ovid Therapeutics (OVID) Invested Capital (2019 - 2020)
Ovid Therapeutics' (OVID) quarterly Invested Capital came in at $2.4 million in Q4 2020, up 21845.5% YoY from N/an in Q1 2020, and up 946.63% on a QoQ basis from $226536.0 in Q3 2020.
Ovid Therapeutics (OVID) Invested Capital (2019 - 2020) Analysis & Trends
Ovid Therapeutics (OVID) has 2 years of Invested Capital data on file, last reported at $2.4 million in Q4 2020.
- Quarterly Invested Capital rose 21845.5% year-over-year to $2.4 million in Q4 2020, while the trailing twelve-month figure through Sep 2021 was $2.4 million (up 815.62% YoY) and the FY2020 annual result came in at $2.4 million, up 21845.5% from the prior year.
- Invested Capital climbed to $2.4 million in Q4 2020, from $226536.0 in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $2.4 million in Q4 2020 to a low of $10804.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 190.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 380.00 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 2.37 Mn |
| Sep 30, 2020 | 226,536.00 |
| Jun 30, 2020 | 10,804.00 |
| Mar 31, 2020 | 10,804.00 |
| Dec 31, 2019 | 10,804.00 |
| Sep 30, 2019 | 337,773.00 |
| Jun 30, 2019 | 1.06 Mn |